Oxford BioDynamics (LSE:OBD) delivered modest revenue growth in its interim results, with revenue increasing to £0.69 million while the operating loss narrowed to £4.68 million. A £6.32 million equity fundraising strengthened the balance sheet, lifting period-end cash to £2.51 million. Despite these improvements, the board warned that additional funding will be required by late August 2026, even as demand for its U.S. prostate screening test continues to build.
Orion platform rollout gains momentum
The company recorded a sharp increase in Prostate Screening EpiSwitch (PSE) test volumes and expanded its media profile in the United States during the period. Oxford BioDynamics also introduced its cloud-based EpiSwitch Orion platform, which is already being used by leading research institutions and is under evaluation in discussions with three major pharmaceutical companies. To support commercial execution, the group appointed diagnostics industry veteran Richard Compton as chief executive officer, added a new non-executive director and engaged a third-party sales organisation. These initiatives are intended to accelerate adoption of Orion and additional products, including the ME/CFS blood test, while pursuing non-dilutive funding opportunities and enhancing shareholder value.
Outlook
Oxford BioDynamics continues to face financial headwinds despite improving commercial traction. Persistent losses, elevated leverage and deteriorating free cash flow remain significant challenges, while technical indicators suggest the shares remain in a downtrend, with only limited support from near-oversold momentum signals. Valuation also offers little encouragement, reflecting the company’s loss-making position and the absence of a dividend.
More about Oxford BioDynamics
Oxford BioDynamics is an AIM-listed biotechnology company specialising in precision diagnostic blood tests and its proprietary EpiSwitch 3D genomics platform. Its commercial offering includes the EpiSwitch Prostate Screening test and the Checkpoint Inhibitor Response Test, with operations spanning the UK, United States and Malaysia, alongside an expanding focus on pharmaceutical and biotechnology data partnerships.
The company’s cloud-based EpiSwitch Orion platform transforms standard and legacy sequencing datasets into actionable 3D genomic insights, enabling the analysis of non-coding disease variants that conventional genomics approaches often miss. Supported by an extensive disease-focused knowledge base, Oxford BioDynamics aims to advance drug target discovery, predictive biomarker development and precision medicine across oncology, neurology, inflammatory diseases and other therapeutic areas.
Leave a Reply